[Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
The effect of a combination of clofibrate and inositol nicotinate (Liporeduct forte, Liporeduct) on lipids and lipoproteins in 20 patients with primary hyperlipoproteinemia (10 type IIa, 7 type IV and 3 tyV) was investigated over a period of 16 weeks. The daily doses of clofibrate and inositol nicotinate was 1,5 g and 2,4 g in the type IIa and 1,5 g and 900 mg in the types IV and V. Placebo was given before and after the treatment period. In the type IIa total cholesterol decreased from 345 +/- 35 to 285 +/- 31 mg/dl; the triglycerides were lowered from 121 +/- 12 to 94 +/- 7 mg/dl. These changes were mainly due to a decrease in low density lipoprotein (LDL)-cholesterol by 18% and a reduction in very low density lipoprotein (VLDL)-triglycerides of 42%. In the types IV and V a triglyceride reduction of 30% and 76% could be observed. In both types, these changes were mainly caused by a decrease in VLDL-triglycerides (type IV: -34%; type V -77%). Total cholesterol was influenced insignificant in these two types. High density lipoprotein (HDL)-cholesterol fell in the types IIa and IV; in the type IV an increase of 24% could be observed. Phospholipids and proteins behaved in an analogous fashion. The percentual composition of the lipoprotein fractions VLDL, LDL and HDL didn't change under treatment in the types IIa and IV. In the type V, a shift in the direction of type IV could be observed. The combination of clofibrate and inositol nicotinate was well tolerated.
D002994:Clofibrate / Q000494:pharmacology*; D004338:Drug Combinations / Q000494:pharmacology; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood; D006953:Hyperlipoproteinemia Type IV / Q000097:blood; D006954:Hyperlipoproteinemia Type V / Q000097:blood; D006951:Hyperlipoproteinemias / Q000097:blood*; D007294:Inositol / Q000031:analogs & derivatives* / Q000494:pharmacology; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood; D009539:Nicotinic Acids / Q000494:pharmacology*
D004338:Drug Combinations; D008055:Lipids; D008074:Lipoproteins; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D009539:Nicotinic Acids; D007294:Inositol; C008291:clofibrate, inositol nicotinate drug combination; D002994:Clofibrate
Zur Wirkung einer Clofibrat-Inositolnicotinat-Kombination auf Lipide und Lipoproteine bei primärer Hyperlipoproteinämie der Typen IIa, IV und V.